Alphamab Oncology Ratios and Metrics

Market cap in millions HKD. Fiscal year is January - December.

Millions HKD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr '26 Apr 16, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Capitalization	11,613	9,492	3,368	6,407	10,149	12,743
Market Cap Growth	63.07%	181.81%	-47.42%	-36.88%	-20.36%	-16.28%
Enterprise Value	10,247	7,989	2,154	5,004	8,763	10,814
Last Close Price	11.99	9.80	3.50	6.64	10.80	13.60
PE Ratio	-	-	19.03	-	-	-
PS Ratio	18.43	15.06	4.95	26.58	53.81	71.10
PB Ratio	6.10	4.99	1.73	3.48	5.76	5.55
P/TBV Ratio	6.10	4.99	1.73	3.48	5.76	5.55
P/FCF Ratio	-	-	16.61	-	-	-
P/OCF Ratio	-	-	14.91	-	-	-
EV/Sales Ratio	16.26	12.68	3.16	20.76	46.46	60.34
EV/EBITDA Ratio	-	-	12.24	-	-	-
EV/EBIT Ratio	-	-	20.04	-	-	-
EV/FCF Ratio	-	-	10.62	-	-	-
Debt / Equity Ratio	0.07	0.07	0.10	0.15	0.22	0.34
Debt / EBITDA Ratio	-	-	1.04	-	-	-
Debt / FCF Ratio	-	-	0.98	-	-	-
Net Debt / Equity Ratio	-0.72	-0.72	-0.76	-0.69	-0.64	-0.72
Net Debt / EBITDA Ratio	13.80	13.80	-8.38	4.30	2.57	3.48
Net Debt / FCF Ratio	-	-	-7.27	4.81	2.34	2.82
Asset Turnover	0.26	0.26	0.29	0.10	0.07	0.06
Inventory Turnover	0.67	0.67	0.75	0.77	0.72	0.06
Quick Ratio	5.29	5.29	6.41	5.55	3.72	3.22
Current Ratio	5.68	5.68	6.74	5.84	3.88	3.32
Return on Equity (ROE)	-6.43%	-6.43%	9.49%	-13.04%	-19.00%	-19.91%
Return on Assets (ROA)	-4.42%	-4.42%	2.88%	-9.50%	-11.21%	-9.72%
Return on Capital Employed (ROCE)	-8.40%	-8.40%	5.10%	-17.30%	-25.00%	-20.10%
Earnings Yield	-1.09%	-1.34%	5.25%	-3.62%	-3.63%	-3.97%
FCF Yield	-	-	6.02%	-4.11%	-4.79%	-4.61%
Buyback Yield / Dilution	2.31%	2.31%	-2.53%	-2.50%	-0.11%	-0.62%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.